Cargando…
Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies
Small-cell lung cancer (SCLC) is an aggressive disease with distinct biological and clinical features. The clinical course of SCLC is generally characterised by initial sensitivity to DNA-damaging therapies, followed by early relapse and broad cross resistance to second line agents. Whilst there has...
Autores principales: | McNamee, Nicholas, da Silva, Ines Pires, Nagrial, Adnan, Gao, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179261/ https://www.ncbi.nlm.nih.gov/pubmed/37175833 http://dx.doi.org/10.3390/ijms24098129 |
Ejemplares similares
-
Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023) -
Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres
por: Brown, Lauren J, et al.
Publicado: (2022) -
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
por: McNamee, Megan Jessica, et al.
Publicado: (2021) -
Immunotherapy in non-small cell lung cancer: Update and new insights
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021) -
Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)